What does SCIENCE ET MEDECINE do?

SCIENCE ET MEDECINE is a wholesaler in Waterloo. Private Limited, started on 16 December 1993, 1 establishment.

What is the address of SCIENCE ET MEDECINE?

The registered office of SCIENCE ET MEDECINE is located at Clos de la Commanderie 3, 1410 Waterloo.

Is SCIENCE ET MEDECINE still active?

Yes. According to the CBE (31 October 2026) SCIENCE ET MEDECINE is active, legal situation “Normale toestand”, started on 16 December 1993.

Is SCIENCE ET MEDECINE registered on Peppol?

Yes, SCIENCE ET MEDECINE is registered on the Peppol network with ID 0208:0451433347.

What is the enterprise number of SCIENCE ET MEDECINE?

The enterprise number of SCIENCE ET MEDECINE is BE0451433347.

When was SCIENCE ET MEDECINE founded?

SCIENCE ET MEDECINE was founded on 16 December 1993.

Who are the directors of SCIENCE ET MEDECINE?

According to the 2025 annual accounts, the directors of SCIENCE ET MEDECINE are: Abdelkader DATOUSSAID.

Is SCIENCE ET MEDECINE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 December 1993; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SCIENCE ET MEDECINE make in 2025?

SCIENCE ET MEDECINE recorded a loss after taxes of € 34,752 in financial year 2025.

What is the revenue of SCIENCE ET MEDECINE?

As a small company, SCIENCE ET MEDECINE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,751.

SCIENCE ET MEDECINE (Private Limited) - Waterloo

Dossier SCIENCE ET MEDECINE, printed on 31 October 2026 from databakkes.be/en/0451433347/science-et-medecine. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

SCIENCE ET MEDECINE from Waterloo, company number BE0451433347, closed financial year 2025 with a result of € -34,752 after tax. For that financial year SCIENCE ET MEDECINE recorded a gross margin of € 2,751 and equity of € 91,996. Compared with financial year 2024, the result moved from € -11,540 to € -34,752. The company made a loss. The buffer shrank hard: equity is 54 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.

What it is worth Shrank hard

€ 91,996

▼ 54% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -34,752

▼ 201 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 75,508

▼ 49% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 70,546.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 30,550

▼ 23% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 31,141

▼ 19% vs 2024

€ 7,603 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 4,424

▼ 89% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 147

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 53,054 Revenue 2022: € 53,054 First fiscal year in the series	€ 43,983 Revenue 2023: € 43,983 ▼ 17% vs 2022 (€ 53,054) Unfavourable step	€ 33,657 Revenue 2024: € 33,657 ▼ 23% vs 2023 (€ 43,983) Unfavourable step	-
Gross margin	€ 89,569 Gross margin 2022: € 89,569 First fiscal year in the series	€ -9,528 Gross margin 2023: € -9,528 ▼ € 99,097 vs 2022 (€ 89,569) Unfavourable step	€ 1,277 Gross margin 2024: € 1,277 ▲ € 10,806 vs 2023 (€ -9,528) Favourable step	€ 2,751 Gross margin 2025: € 2,751 ▲ 115% vs 2024 (€ 1,277) Favourable step	▲ 115%
Profit after taxes	€ 49,362 Profit after taxes 2022: € 49,362 First fiscal year in the series	€ -23,122 Profit after taxes 2023: € -23,122 ▼ € 72,484 vs 2022 (€ 49,362) Unfavourable step	€ -11,540 Profit after taxes 2024: € -11,540 ▲ € 11,582 vs 2023 (€ -23,122) Favourable step	€ -34,752 Profit after taxes 2025: € -34,752 ▼ € 23,212 vs 2024 (€ -11,540) Unfavourable step	▼ € 23,212
Equity	€ 241,410 Equity 2022: € 241,410 First fiscal year in the series	€ 215,788 Equity 2023: € 215,788 ▼ 11% vs 2022 (€ 241,410) Unfavourable step	€ 201,748 Equity 2024: € 201,748 ▼ 7% vs 2023 (€ 215,788) Unfavourable step	€ 91,996 Equity 2025: € 91,996 ▼ 54% vs 2024 (€ 201,748) Unfavourable step	▼ 54%
Total debts	€ 17,134 Total debts 2022: € 17,134 First fiscal year in the series	€ 6,292 Total debts 2023: € 6,292 ▼ 63% vs 2022 (€ 17,134) Favourable step	€ 82,184 Total debts 2024: € 82,184 ▲ € 75,892 vs 2023 (€ 6,292) Unfavourable step	€ 35,926 Total debts 2025: € 35,926 ▼ 56% vs 2024 (€ 82,184) Favourable step	▼ 56%
Cash	€ 102,868 Cash 2022: € 102,868 First fiscal year in the series	€ 64,250 Cash 2023: € 64,250 ▼ 38% vs 2022 (€ 102,868) Unfavourable step	€ 148,803 Cash 2024: € 148,803 ▲ 132% vs 2023 (€ 64,250) Favourable step	€ 75,508 Cash 2025: € 75,508 ▼ 49% vs 2024 (€ 148,803) Unfavourable step	▼ 49%
Land & buildings	€ 0 Land & buildings 2022: € 0 First fiscal year in the series	€ 2,358 Land & buildings 2023: € 2,358 Unchanged (€ 0) Unchanged	€ 4,403 Land & buildings 2024: € 4,403 ▲ 87% vs 2023 (€ 2,358) Unchanged	€ 3,379 Land & buildings 2025: € 3,379 ▼ 23% vs 2024 (€ 4,403) Unchanged	▼ 23%
Retained profit	€ 221,910 Retained profit 2022: € 221,910 First fiscal year in the series	€ 196,288 Retained profit 2023: € 196,288 ▼ 12% vs 2022 (€ 221,910) Unfavourable step	€ 182,248 Retained profit 2024: € 182,248 ▼ 7% vs 2023 (€ 196,288) Unfavourable step	€ 70,546 Retained profit 2025: € 70,546 ▼ 61% vs 2024 (€ 182,248) Unfavourable step	▼ 61%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 2,500 Dividend 2023: € 2,500 Unchanged (€ 0) Unchanged	€ 2,500 Dividend 2024: € 2,500 Unchanged (€ 2,500) Unchanged	€ 75,000 Dividend 2025: € 75,000 ▲ € 72,500 vs 2024 (€ 2,500) Unchanged	▲ € 72,500
Bank debt	€ 2,660 Bank debt 2022: € 2,660 First fiscal year in the series	€ 739 Bank debt 2023: € 739 ▼ 72% vs 2022 (€ 2,660) Favourable step	€ 38,518 Bank debt 2024: € 38,518 ▲ € 37,778 vs 2023 (€ 739) Unfavourable step	€ 31,141 Bank debt 2025: € 31,141 ▼ 19% vs 2024 (€ 38,518) Favourable step	▼ 19%
Balance sheet total	€ 258,544 Balance sheet total 2022: € 258,544 First fiscal year in the series	€ 222,080 Balance sheet total 2023: € 222,080 ▼ 14% vs 2022 (€ 258,544) Unchanged	€ 283,932 Balance sheet total 2024: € 283,932 ▲ 28% vs 2023 (€ 222,080) Unchanged	€ 127,922 Balance sheet total 2025: € 127,922 ▼ 55% vs 2024 (€ 283,932) Unchanged	▼ 55%

Key figures of SCIENCE ET MEDECINE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SCIENCE ET MEDECINE?

What happened at SCIENCE ET MEDECINE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 11, 2026 New annual accounts for financial year 2025: loss of € 34,752. Source: NBB ↗
2023 Abdelkader DATOUSSAID became a director. NBB
Dec 16, 1993 Start of the company according to the CBE. KBO
Dec 15, 1993 New establishment in Waterloo. KBO

In short

From € 49,362 profit in 2022 to € 34,752 loss in 2025.

Paid € 35,705 in corporate taxes since 2022.

Best year ever: 2022, with € 49,362 profit.

Paid out € 80,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Abdelkader DATOUSSAID

SCIENCE ET MEDECINE

Behind SCIENCE ET MEDECINE is Abdelkader DATOUSSAID.

Directors

According to the 2025 annual accounts

Abdelkader DATOUSSAID

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Clos de la Commanderie 3

1410 Waterloo

2.064.663.608

Avenue du Printemps 22

1410 Waterloo

Active since 15 December 1993

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

ETMA.BE

THERAPIES K

€ 10,226 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0451.433.347

VAT number

BE 0451.433.347

Registered office

Clos de la Commanderie 3, 1410 Waterloo

Names & denominations

SCIENCE ET MEDECINE · SCI - MED

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 December 1993

Peppol

Active · Active since 27 Feb 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗